Carta Healthcare, an AI company focused on accelerating data abstraction, has acquired Realyze Intelligence, a leader in using AI to match patients with clinical trials. This strategic acquisition aims to merge their technologies to create a more powerful AI platform designed to streamline clinical research and lower costs, particularly in oncology. Realyze’s AI platform excels at analyzing both structured and unstructured data from electronic health records (EHRs), enabling faster and more accurate identification of patients eligible for clinical trials. It dramatically reduces the time spent on manual patient matching, which typically takes hours or even days, by automating the process in seconds.
The collaboration will integrate Realyze's AI technology with Carta’s platform, which specializes in reducing the time and cost associated with data abstraction. This combined technology is expected to speed up insights, lower labor costs, and enhance clinical data registry abstraction, not only in oncology but also in cardiovascular health and other specialty areas. By improving clinical trial matching, the companies aim to increase the feasibility of research, expand trial participation, and improve data collection for cancer and other clinical registries.
Both companies emphasize the importance of high-quality, timely data in improving healthcare outcomes. Brent Dover, CEO of Carta Healthcare, highlighted the challenge faced by clinicians in handling vast amounts of data trapped in EHRs, which has the potential to improve care practices but is often difficult to access and analyze. Aaron Brauser, CEO of Realyze Intelligence, noted that the traditional clinical trial matching process is costly, labor-intensive, and slow, but the integration of their AI-driven systems can significantly optimize this process, enhancing research and ultimately improving patient care. This collaboration positions both companies to transform how clinical trials are conducted and how healthcare data is leveraged for better patient outcomes.
Click here to read the original news story.